Variant sequences: the new frontier in sequence IP

A variant sequence is typically a naturally-occurring molecule, most frequently protein, which has been modified in order to impart desired characteristics such as improved stability under anticipated use conditions, or increased activity. Optimising sequences and, of course, the associated IP rights, span most areas of biotechnology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Blow for Masimo’s fight with Apple as case against US Customs dismissed

29 April 2026 The wearable tech company has had to drop its lawsuit against US Customs and Border Protection, part of the wider, ongoing dispute with Apple over a blood oxygen feature in smart watches.

Americas

Ligand buys biotech in $739m cash deal with litigation sweetener

28 April 2026 Pharma group strikes an all-cash transaction, combining a portfolio expansion with a contingent payment linked to a dispute over a $5 billion drug

Americas

CureVac targets Moderna with 10-patent suit over Spikevax

28 April 2026 BioNTech’s former rival—now part of its company—is seeking to assert its mRNA portfolio against Moderna in a new suit over modifications to the highly fought-over molecule.

More features

CureVac targets Moderna with 10-patent suit over Spikevax

EU court under pressure to define SPC limits in patent row

Amneal acquires biopharma ahead of $300bn patent wave

Litigator from Brown Rudnick moves firms to chair practice

Penile implant maker’s $17m trade secret award unravels

Appeals court eases Teva’s headache with reversal

Cancer drug researcher hit with suit over mutation-targeting tools

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

Variant sequences: the new frontier in sequence IP

More on this story

Editor's picks

Editor's picks

More features